Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTX NASDAQ:ECOR NASDAQ:IPSC OTCMKTS:PRVCF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTXAvalo Therapeutics$4.88+1.6%$4.43$3.39▼$16.00$52.80M0.7764,114 shs4,683 shsECORelectroCore$7.10+2.1%$5.52$4.47▼$19.49$52.65M0.8105,988 shs9,439 shsIPSCCentury Therapeutics$0.59+1.1%$0.57$0.34▼$3.29$50.40M1.78571,161 shs158,006 shsPRVCFPreveCeutical Medical$0.03+20.8%$0.03$0.01▼$0.03$14.61M0.3440,817 shs11,812 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTXAvalo Therapeutics-2.04%-1.03%-0.83%+3.67%-60.82%ECORelectroCore-6.71%-2.11%+36.54%+16.22%+10.67%IPSCCentury Therapeutics-3.58%+2.83%+0.52%+15.68%-78.97%PRVCFPreveCeutical Medical+20.75%+16.89%-4.48%+6.22%+28.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVTXAvalo Therapeutics3.1241 of 5 stars3.53.00.00.02.71.71.3ECORelectroCore3.4014 of 5 stars3.54.00.00.03.32.50.6IPSCCentury Therapeutics3.2441 of 5 stars3.55.00.00.02.41.70.6PRVCFPreveCeutical MedicalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTXAvalo Therapeutics 3.00Buy$30.00515.38% UpsideECORelectroCore 3.00Buy$25.50259.41% UpsideIPSCCentury Therapeutics 3.00Buy$4.20617.95% UpsidePRVCFPreveCeutical Medical 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PRVCF, AVTX, IPSC, and ECOR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025AVTXAvalo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$15.005/16/2025IPSCCentury TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $6.00(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTXAvalo Therapeutics$440K119.99N/AN/A$12.80 per share0.38ECORelectroCore$26.46M1.99N/AN/A$1.13 per share6.28IPSCCentury Therapeutics$6.59M7.65N/AN/A$1.90 per share0.31PRVCFPreveCeutical MedicalN/AN/AN/AN/A($0.01) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTXAvalo Therapeutics-$35.13MN/A0.00N/AN/AN/A111.00%58.88%8/11/2025 (Estimated)ECORelectroCore-$11.89M-$1.56N/AN/AN/A-46.24%-149.04%-61.24%8/6/2025 (Estimated)IPSCCentury Therapeutics-$126.57M-$0.29N/AN/AN/A-19.10%-10.71%-5.96%8/14/2025 (Estimated)PRVCFPreveCeutical Medical-$940KN/A0.00∞N/AN/AN/AN/AN/ALatest PRVCF, AVTX, IPSC, and ECOR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025AVTXAvalo Therapeutics-$1.43N/AN/AN/AN/AN/A8/6/2025Q2 2025ECORelectroCore-$0.32N/AN/AN/A$7.24 millionN/A5/15/2025Q1 2025IPSCCentury Therapeutics-$0.31$0.89+$1.20$0.89$45.52 million$109.16 million5/12/2025Q1 2025AVTXAvalo Therapeutics-$1.07-$1.25-$0.18-$1.25N/AN/A5/7/2025Q1 2025ECORelectroCore-$0.56-$0.47+$0.09-$0.47$6.93 million$6.72 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVTXAvalo TherapeuticsN/AN/AN/AN/AN/AECORelectroCoreN/AN/AN/AN/AN/AIPSCCentury TherapeuticsN/AN/AN/AN/AN/APRVCFPreveCeutical MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTXAvalo TherapeuticsN/A22.6122.61ECORelectroCoreN/A1.521.30IPSCCentury TherapeuticsN/A11.7011.70PRVCFPreveCeutical MedicalN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTXAvalo Therapeutics87.06%ECORelectroCore26.74%IPSCCentury Therapeutics50.20%PRVCFPreveCeutical MedicalN/AInsider OwnershipCompanyInsider OwnershipAVTXAvalo Therapeutics0.25%ECORelectroCore19.70%IPSCCentury Therapeutics5.00%PRVCFPreveCeutical MedicalN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTXAvalo Therapeutics4010.83 million10.80 millionNot OptionableECORelectroCore507.42 million5.96 millionNot OptionableIPSCCentury Therapeutics17086.16 million81.85 millionOptionablePRVCFPreveCeutical MedicalN/A570.65 millionN/ANot OptionablePRVCF, AVTX, IPSC, and ECOR HeadlinesRecent News About These CompaniesPreveCeutical Announces Rescheduled Date for Annual General and Special MeetingJuly 9, 2025 | newsfilecorp.comNPRVCF PreveCeutical Medical Inc. - Seeking AlphaJuly 2, 2025 | seekingalpha.comPreveCeutical Appoints Dr. Francis Tavares as CTO to Enhance Drug Discovery EffortsJune 30, 2025 | tipranks.comPreveCeutical Welcomes Dr. Francis Tavares, PhD. As Chief Technology OfficerJune 30, 2025 | newsfilecorp.comNPreveCeutical Announces Date for Annual General and Special MeetingJune 25, 2025 | newsfilecorp.comNPreveCeutical Announces Non-Brokered Private PlacementJune 11, 2025 | newsfilecorp.comNPreveCeutical Appoints Dr. Deepak Sampath as Corporate AdvisorJune 2, 2025 | tipranks.comPreveCeutical Appoints Stephen Glover as Corporate Advisor to Boost Strategic GrowthMay 26, 2025 | tipranks.comPreveCeutical Welcomes Stephen Glover as Corporate AdvisorMay 26, 2025 | newsfilecorp.comNPreveCeutical Completes Private Placement to Boost R&D EffortsMay 22, 2025 | tipranks.comPreveCeutical Closes Final Tranche of Up-Sized Non-Brokered Private PlacementMay 22, 2025 | newsfilecorp.comNPreveCeutical’s BioGene Launches New Website to Boost Digital EngagementMay 14, 2025 | tipranks.comPreveCeutical Medical Inc. Announces Launch of New Website for BioGene Therapeutics Inc. ...May 14, 2025 | gurufocus.comPreveCeutical Medical Inc. Announces Launch of New Website for BioGene Therapeutics Inc., Expanding Its Digital Presence to Enhance Accessibility and Awareness of Innovative TherapiesMay 14, 2025 | newsfilecorp.comNPreveCeutical Closes Initial Tranche of Private Placement, Raising $590,001April 28, 2025 | tipranks.comPreveCeutical Closes Initial Tranche of Up-Sized Non-Brokered Private PlacementApril 28, 2025 | newsfilecorp.comNPreveCeutical Upsizes Private Placement to Bolster Financial PositionApril 15, 2025 | tipranks.comPreveCeutical Announces Up-Sized Non-Brokered Private PlacementApril 14, 2025 | newsfilecorp.comNPreveCeutical Announces Update to Non-Brokered Private PlacementApril 2, 2025 | newsfilecorp.comNPreveCeutical Launches Private Placement to Raise $500,000April 2, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRVCF, AVTX, IPSC, and ECOR Company DescriptionsAvalo Therapeutics NASDAQ:AVTX$4.88 +0.08 (+1.56%) As of 10:47 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.electroCore NASDAQ:ECOR$7.10 +0.15 (+2.09%) As of 10:48 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.Century Therapeutics NASDAQ:IPSC$0.58 +0.01 (+1.14%) As of 10:48 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.PreveCeutical Medical OTCMKTS:PRVCF$0.03 +0.00 (+20.75%) As of 07/15/2025 03:53 PM EasternPreveCeutical Medical Inc., a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products. Its pipeline products include Cannabinoid Sol-Gel Delivery, a cannabinoid-based nose-to-brain delivery system that provides relief from various indications, including pain, inflammation, seizures, and neurological disorders; Non-Addictive Analgesic for pain management; BSV Peptide Program that targets cancer progression; and Dual Gene Therapy for type 2 diabetes and obesity. PreveCeutical Medical Inc. is headquartered in West Vancouver, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Delta Air Lines Stock Rallies on New Guidance—Can It Keep Going? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
